Ownership and insider activity for Outlook Therapeutics, Inc. (OTLK): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials.
Price
| Price | $0.68 |
| Market Cap | $127M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-01 | Lundquist Kevin Michael | A-Award | 500,000 | $315K |
| 2026-09-01 | Lundquist Kevin Michael | |||
| 2026-08-14 | Jahr Robert Charles | P-Purchase | 151,515 | $150K |
| 2026-08-14 | Jahr Robert Charles | P-Purchase | 151,515 | $167K |
| 2026-08-12 | Sukhtian Ghiath M. | P-Purchase | 2,525,252 | $2.5M |
| 2026-08-12 | Sukhtian Ghiath M. | P-Purchase | 2,525,252 | $2.8M |
| 2026-08-14 | KENYON LAWRENCE A | P-Purchase | 101,010 | $100K |
| 2026-08-14 | KENYON LAWRENCE A | P-Purchase | 101,010 | $111K |
| 2026-07-29 | Sukhtian Faisal Ghiath | P-Purchase | 95,398 | $100K |
| 2026-07-21 | KENYON LAWRENCE A | A-Award | 210,078 | $300K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.4M | $3.2M | $1.7M | $8.0M | $12.5M | $14.5M | $17.4M | $23.4M | $14.9M | $8.1M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $3.3M |
| Total Current Assets | $5.7M | $3.9M | $3.3M | $13.5M | $17.9M | $21.5M | $27.5M | $31.0M | $27.4M | $17.4M |
| Property, Plant & Equipment | $17.0M | $16.1M | $18.5M | $3.2M | $494235 | $275054 | $70360 | $26172 | $274645 | $225508 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $23.7M | $20.7M | $22.3M | $17.1M | $19.7M | $22.8M | $28.5M | $32.3M | $28.8M | $18.6M |
| Accounts Payable | $5.1M | $11.0M | $3.6M | $2.3M | $2.4M | $2.2M | $3.5M | $6.6M | $8.0M | $10.2M |
| Short-term Debt | $5.2M | $4.7M | $17.9M | $11.3M | $3.7M | $904200 | $10.9M | $35.6M | $29.4M | $29.9M |
| Total Current Liabilities | $20.4M | $28.7M | $32.0M | $20.3M | $15.9M | $6.8M | $19.7M | $46.7M | $42.6M | $45.8M |
| Long-term Debt | $2.2M | $13.4M | $98487 | $50285 | $904200 | $10.9M | 0 | 0 | 0 | 0 |
| Total Liabilities | $28.9M | $51.5M | $43.1M | $27.9M | $16.9M | $18.2M | $19.8M | $46.7M | $101.9M | $50.8M |
| Retained Earnings | -$147.4M | -$186.2M | -$216.3M | -$254.5M | -$289.7M | -$342.9M | -$408.9M | -$467.9M | -$543.3M | -$605.7M |
| Total Equity | -$5.2M | -$30.7M | -$20.8M | -$10.8M | $2.8M | $4.6M | $8.7M | -$14.4M | -$73.1M | -$32.2M |
| Total Debt | $8.7M | $18.4M | $21.9M | $14.9M | $8.8M | $11.9M | $11.0M | $35.6M | $29.7M | $30.2M |
| Net Debt | $6.4M | $15.2M | $20.2M | $6.9M | -$3.7M | -$2.6M | -$6.4M | $12.2M | $14.8M | $22.1M |
| Working Capital | -$14.8M | -$24.8M | -$28.7M | -$6.8M | $2.1M | $14.8M | $7.8M | -$15.8M | -$15.1M | -$28.4M |
Financial Health
| Debt / Equity | -1.77 |
| Current Ratio | 0.81 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -58.86 |
Profitability
| Return on Equity | 222.01% |
| Return on Invested Capital | -343.68% |
| Return on Assets | -233.43% |
| Gross Margin | 195.64% |
| Operating Margin | 4783.05% |
| Net Margin | 5254.81% |
Related companies: COEP · CUE · EQ · HOWL · IOBT · IPSC · MDCX
Explore sector: Healthcare · Biotechnology
More sections of OTLK: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks